Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

EKSO vs KMTS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

EKSO Wins Head-to-Head Institutional Verdict (3–1 across 6 Pillars · 4–4 Matrix Metrics)

EKSO Overall Winner 6-Pillar Tally: EKSO 3 – 1 KMTS (2 Tie) Matrix Metrics: EKSO 4 – 4 KMTS

As of Nov 20, 2026, Ekso Bionics Holdings, Inc. (EKSO) is the stronger overall head-to-head candidate over Kestra Medical Technologies, Ltd. (KMTS) in the Tradestie Institutional Equity Comparison Engine, winning 4–4 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). EKSO carries a Unified Composite Score of 58.1/100 (HOLD) at $11.80 (N/M Forward P/E, -119.7% operating margin), whereas KMTS carries 46.9/100 (HOLD) at $25.10 (N/M Forward P/E, -134.5% operating margin).

  • Growth vs. Quality Trade-Off: EKSO earns the overall head-to-head edge with a stronger Unified Composite Score (58.1/100 HOLD vs. KMTS 46.9/100 HOLD) and 2.16β · 76% Vol risk profile, whereas KMTS leads top-line expansion (+59.9% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About EKSO vs KMTS
EKSO NASDAQ Head-to-Head Winner
Ekso Bionics Holdings, Inc. Common Stock
General Industrial Machinery & Equipment, Nec
$11.80
+0.08% 1D
Market Cap $42.0M
TTM Revenue $13M
Forward P/E N/M
Beta / 30D Vol 2.16β · 76% Vol
Unified Composite Score
58.1 / 100 HOLD
Tech 60.0 Fund 54.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (3.2% over 20 days), RSI 60
RSI-14: 60.4 · SMA20: $10.56 · SMA50: $10.65
KMTS NASDAQ
Kestra Medical Technologies, Ltd. Common Stock
Surgical & Medical Instruments & Apparatus
$25.10
-5.75% 1D
Market Cap $1.6B
TTM Revenue $107M
Forward P/E N/M
Beta / 30D Vol 1.74β · 63% Vol
Unified Composite Score
46.9 / 100 HOLD
Tech 37.0 Fund 43.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 38
RSI-14: 37.6 · SMA20: $29.05 · SMA50: $27.68

6-Pillar Scorecard Institutional Category Breakdown (EKSO 3 – 1 KMTS)

Columns: Metric · EKSO · KMTS
1. Valuation Multiples EKSO
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 3.3x 14.4x
2. Growth & Scale KMTS
Revenue Growth (YoY) -38.3% +59.9%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $13M $107M
Market Cap $42.0M $1.6B
3. Profitability & Quality EKSO
Gross Margin 53.5% 53.9%
Operating Margin -119.7% -134.5%
Net Profit Margin -91.4% -140.4%
Return on Equity (ROE) -107.6% -73.7%
4. Balance Sheet & Cash Flow EKSO
Cash Generation (TTM) -$11M EBITDA -$117M
Cash Flow Margin -86.0% EBITDA Mgn -109.7%
Net Cash / Leverage $2.54 Book/Sh · -107.6% ROE $53M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Instruments & Supplies Operator Medical Instruments & Supplies Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: EKSO (4) vs KMTS (4)
Institutional Metric EKSO KMTS Criterion Row Edge
Market Capitalization
Scale
$42.0M $1.6B Larger Scale KMTS
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-38.3% +59.9% Higher Growth KMTS
Operating Margin (TTM)
Profitability
-119.7% -134.5% Higher Margin EKSO
Net Profit Margin
Profitability
-91.4% -140.4% Higher Margin EKSO
Return on Equity (ROE)
Capital Efficiency
-107.6% -73.7% Higher ROE KMTS
52-Week Range Position
Momentum
87% ($0–$14) 53% ($17–$32) Stronger Trend EKSO
Beta / 30D Volatility
Risk Regime
2.16β · 76% Vol 1.74β · 63% Vol Lower Realized Risk KMTS
Unified Institutional Score
Composite Signal
58.1 / 100 (HOLD) 46.9 / 100 (HOLD) Higher Composite EKSO
Trailing 12M Revenue (USD)
Operating Scale
$13M $107M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
53.5% 53.9% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 3.3x EV/Rev N/M PEG · 14.4x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$11M EBITDA ($2.54 Book/Sh · -107.6% ROE) -$117M ($53M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon EKSO +21.95 pp
EKSO: +25.53% · KMTS: +3.58%
3M Horizon EKSO +43.73 pp
EKSO: +25.93% · KMTS: -17.8%
6M Horizon EKSO +213.24 pp
EKSO: +192.8% · KMTS: -20.44%
1Y Horizon EKSO +213.24 pp
EKSO: +192.8% · KMTS: -20.44%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on EKSO vs KMTS. Trailing 12-month operating profitability (EKSO -119.7% vs KMTS -134.5%) and valuation multiples (EKSO N/M vs KMTS N/M Forward P/E) are benchmarked directly in Pillar 4 below.

EKSO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$13M
Gross Margin53.5%
Op. Margin-119.7%
ROE / Fwd P/E-107.6% · N/M
KMTS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$107M
Gross Margin53.9%
Op. Margin-134.5%
ROE / Fwd P/E-73.7% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
EKSO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact EKSO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
KMTS UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact KMTS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
EKSO Moat Profile Cyclical / Execution-Driven Positioning
Medical Instruments & Supplies Operator
Competes within the Medical Instruments & Supplies value chain with $42.0M market capitalization and -119.7% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
KMTS Moat Profile Cyclical / Execution-Driven Positioning
Medical Instruments & Supplies Operator
Competes within the Medical Instruments & Supplies value chain with $1.6B market capitalization and -134.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ EKSO vs KMTS Key Questions & Quantitative Answers

As of Nov 20, 2026, Ekso Bionics Holdings, Inc. (EKSO) is the stronger overall head-to-head candidate over Kestra Medical Technologies, Ltd. (KMTS) in the Tradestie Institutional Equity Comparison Engine, winning 4–4 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). EKSO carries a Unified Composite Score of 58.1/100 (HOLD) at $11.80 (N/M Forward P/E, -119.7% operating margin), whereas KMTS carries 46.9/100 (HOLD) at $25.10 (N/M Forward P/E, -134.5% operating margin). Growth vs. Quality Trade-Off: EKSO earns the overall head-to-head edge with a stronger Unified Composite Score (58.1/100 HOLD vs. KMTS 46.9/100 HOLD) and 2.16β · 76% Vol risk profile, whereas KMTS leads top-line expansion (+59.9% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.

KMTS leads the Growth & Scale pillar: EKSO posts -38.3% YoY revenue growth and +0.0% YoY earnings growth on $13M TTM revenue (53.5% gross margin, -119.7% operating margin), compared with KMTS at +59.9% YoY revenue growth and +0.0% YoY earnings growth on $107M TTM revenue (53.9% gross margin, -134.5% operating margin). On trailing 12-month operating scale, EKSO generates $13M in USD-normalized revenue versus $107M for KMTS. In operating R&D and SG&A reinvestment, EKSO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for KMTS.

EKSO screens cheaper on headline valuation multiples. EKSO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 3.3x EV/Revenue (-86.0% EBITDA margin), whereas KMTS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 14.4x EV/Revenue (-109.7% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against EKSO (-107.6% ROE) versus KMTS (-73.7% ROE) capital efficiency.

In options market volatility and institutional positioning, EKSO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.16β · 76% Vol realized risk). By comparison, KMTS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.74β · 63% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.